Recently, evidence substantiating the role of RAD51C and RAD51D in BC predisposition was published,8 which suggests further amendments to the test directory may be required (see table 1 for a summary of studies assessing BC risk for RAD51C and RAD51D). This evidence concerns the gene RAD51C and breast cancer.